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Background: Although most patients with autoimmune pancreatitis (AIP) respond favorably to prednisolone
therapy, some individuals who later suffer from pancreatic calculi may require additional extracorporeal shock wave
lithotripsy (ESWL) treatment. This study compares the efficacy of ESWL for calculi in AIP with that in ordinary
chronic pancreatitis (CP) and proposes a new treatment approach for pancreatic duct stones occurring in AIP.
Methods: We examined the clinical records of 8 patients with chronic stage AIP and 92 patients with ordinary CP
who received ESWL for pancreatic calculi.
Results: The AIP group was significantly older than the CP group (69.0 vs. 56.5 years, P = 0.018). With regard to the
indications for ESWL, chronic pain was significantly less frequent in the chronic stage AIP group (0% vs. 45.7%,
P = 0.001), whereas preservation of pancreatic function was significantly more frequent (75% vs. 19.6%, P = 0.001).
Compared with the CP group, the AIP group tended to exhibit pancreatic duct stenosis proximal to pancreatic
calculi and had a lower rate of complete extraction of stones from the main pancreatic duct. Histopathological
analysis of a patient with chronic stage AIP revealed widely distributed nodular pancreatitis, which was
characteristic of ordinary CP, along with isolated areas of lymphoplasmacytic sclerosing pancreatitis.
Conclusions: Different approaches are needed for the treatment of pancreatic calculi in chronic stage AIP and
ordinary CP. Specifically, it appears that intensive ESWL therapy can be avoided or delayed in AIP if the patient
displays: (1) advanced age, (2) little or no chronic pain or pancreatitis, and (3) pancreatic duct stenosis proximal to
pancreatic stones. In such cases, the benefit of ESWL treatment may be outweighed by the risks involved in this
procedure.
Keywords: Autoimmune pancreatitis, Chronic pancreatitis, Pancreatic stone, Pancreatic calculi, Extracorporeal shock
wave lithotripsy, Endoscopic retrograde cholangiopancreatographyBackground
Autoimmune pancreatitis (AIP) has been recognized as
a distinct type of pancreatitis that is possibly caused by
autoimmune mechanisms [1-3]. AIP is characterized by
pancreatic enlargement and irregular narrowing of the
main pancreatic duct (MPD), both of which mimic the
imaging features of pancreatic cancer [4-8]. Other prom-
inent manifestations in AIP include high serum IgG4* Correspondence: skawapc@shinshu-u.ac.jp
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unless otherwise stated.concentration and IgG4-positive plasma cell infiltration
in the affected pancreatic tissue, which are useful for sero-
logical and pathological diagnosis, respectively [9-11].
Patients with AIP respond favorably to prednisolone
(PSL) therapy from the clinical, serological, imaging,
and pathological perspectives [12-16].
In 1995, Yoshida et al. first proposed a concept of AIP
that did not include pancreatic calcification [4]. As AIP
patients responded favorably to corticosteroid therapy,
the disease was believed to be a non-progressive condi-
tion that did not lead to pancreatic stone formation,
which was a characteristic feature of advanced stagetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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some patients with AIP experienced pancreatic calculi
formation, pancreatic atrophy, and/or irregular dilatation
of the MPD over a long-term course [14,17-26]. Such
imaging findings corresponded to those of CP, suggest-
ing that AIP could progress to a chronic state. We earl-
ier reported that pancreatic calcification was closely
associated with relapse and that AIP could develop into
confirmed CP after multiple recurrences [17]. Hart et al.
later conducted an international survey of AIP and
found that 46 of 659 patients (7%) experienced pancre-
atic calcification, which supported the hypothesis that a
chronic condition was significantly more frequent in re-
lapse than in non-relapse individuals [14]. We also dis-
covered that a primary risk factor for pancreatic stone
formation in AIP was narrowing of both Wirsung’s and
Santorini’s ducts in the pancreatic head region at the
time of diagnosis [27]. Furthermore, we identified that
the major risk factors for AIP developing into CP that
satisfied the Revised Japanese Clinical Diagnostic Criteria
(JCDC) for Ordinary Chronic Pancreatitis [28] were pan-
creatic head swelling and MPD non-narrowing in the pan-
creatic body [29]. Collectively, these findings suggested
that AIP could progress to confirmed CP with severe pan-
creatic stone formation over a long-term period, most pre-
sumably due to disease recurrence and pancreatic juice
stasis from remnant pancreatic duct stenosis [30].
Extracorporeal shock wave lithotripsy (ESWL) is gen-
erally considered to be effective for the treatment of
pancreatic duct stones in ordinary CP [31-36]. However,
there are few reports on the treatment of pancreatic duct
calculi in AIP, and an effective therapeutic course has
not been fully established owing to the different patho-
physiologies of AIP and ordinary CP. Many patients with
AIP experience pancreatic head swelling during the
acute stage that leads to remnant narrowing of the MPD
in the region [27,29]. This pathological condition creates
problems in the drainage of crushed pancreatic stones,
even after ESWL, and reduces the therapeutic effective-
ness of pancreatic stone removal in AIP. Accordingly, an
alternative perspective on for the treatment of pancreatic
duct stones in AIP is needed. This study evaluated
whether the efficacy of ESWL treatment for pancreatic
duct stones in AIP was comparable with that in ordinary
CP and proposed a new therapeutic approach for
chronic stage AIP patients.
Methods
Study subjects
This retrospective study examined the ESWL records of
8 patients with chronic stage AIP and 92 patients with
ordinary CP that were obtained between March 1996
and August 2012 at Shinshu University Hospital. During
the study period, 73 AIP patients were registered at ourhospital, which included 56 men and 17 women (median
age: 66 years, range: 38–84 years). Of them, 63 patients
(86%) received steroid therapy and 15 patients (20%) ex-
perienced calculi formation that met the Japanese diag-
nostic criteria for ordinary CP. The indications for
ESWL were the following: (1) obstructing stone in the
MPD whose volume was deemed too large for endo-
scopic therapy or for which therapeutic endoscopy had
already been unsuccessful, (2) chronic pain or repeated
pancreatitis attacks, and (3) preservation of pancreatic
function by pancreatic juice release. Pancreatic function
in the context of this study was defined as the mainten-
ance of a normal pancreatic condition, including the ab-
sence of advanced diabetes mellitus and severe indigestion
due to pancreatic dysfunction. Patients with malignancies
were excluded following extensive examination using
endoscopic ultrasound-guided fine needle aspiration
(EUS-FNA) for any suspected cases. ESWL was performed
by two or more pancreatology experts using a Piezolith
2500 lithotriptor (Piezoelectric effect technique; Richard
Wolf GmbH, Knittlingen, Germany) before 2004 and a
LITHOSTAR Multiline (Electromagnetic generation tech-
nique; Siemens GmbH, Munich, Germany) afterwards.
ESWL sessions consisted of 3000 shocks over 60 minutes
and were performed twice per week. Technical success of
ESWL was defined as: (1) adequate stone fragmentation
allowing extraction by therapeutic endoscopy or (2) the
absence of targeted stones in follow-up radiographs.
For the treatment of chronic calcified pancreatitis, im-
aging tests, including ultrasound, CT, MRI, and/or endo-
scopic ultrasound, were first performed to confirm stone
and duct morphology. Next, diagnostic endoscopic retro-
grade cholangiopancreatography (ERCP) was conducted
to identify the stones obstructing the MPD. Therapeutic
endoscopy was initially attempted for all cases. Endoscopic
pancreatic sphincterotomy (EPST) was performed prior to
ESWL whenever possible. Treated stones were primarily
identified by the above imaging modalities. However,
when other radiolucent stones were detected by ERP that
met the indications for ESWL, a nasopancreatic tube was
inserted to visualize the stones as negative images using
contrast material to aid in ESWL therapy. Therapeutic
ERCP was done for all patients within 4 days after ESWL.
The clearance of residual fragmented stones in the MPD
was performed by endoscopic pancreatolithotripsy mainly
via a conventional basket. Endoscopic pancreatic stenting
(EPS) was carried out if dominant strictures were present
or when MPD clearance was deemed as inadequate.
We classified cases of CP as either chronic stage AIP
or ordinary CP according to disease etiology. AIP diag-
nosis was based on the International Consensus Diag-
nostic Criteria (ICDC) for AIP [37], and all patients
were diagnosed as having type 1 AIP. The diagnosis of
ordinary CP was made according to the Revised JCDC
Table 2 Comparison of clinical features, treatment
details, and outcomes between patients with
autoimmune pancreatitis and chronic pancreatitis
AIP (n = 8) CP (n = 92) P value
Clinical features Median (range)
Age (years) 69.0 (59–73) 56.5 (20–85) 0.018*
Gender (male/female) 7/1 77/15 1.000
Therapeutic purpose for ESWL
Chronic pain (+/−) 0/8 42/50 0.019*





Location of treated pancreatic
stones
Pancreatic head 6/2 83/9 0.213
Pancreatic body 3/5 15/77 0.153
Pancreatic tail 0/8 1/91 1.000
Pancreatic duct stenosis
proximal to stones (+/−)
4/4 22/70 0.107
Endoscopic treatment 6/2 66/26 1.000
Endoscopic pancreatic 3/5 39/53 1.000
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pancreatic stone formation and marked calcification
were the main diagnostic items. To clarify the differ-
ences in efficacy of ESWL pancreatic stone treatment
between chronic stage AIP and ordinary CP, we com-
pared clinical features, treatment details, and outcomes.
Statistical analysis
Fisher’s exact and Pearson’s chi-square tests were
adopted to test for differences between subgroups of pa-
tients. The Mann–Whitney U test was employed to
compare continuous data. Multivariate analyses were
performed using a logistic regression model. All tests
were done using StatFlex ver. 6 software for Windows
(Artec, Osaka, Japan). P values of less than 0.05 were
considered to be statistically significant.
Ethics




The clinical findings of the 8 patients (7 men and 1
woman) with chronic stage AIP having undergone
ESWL for pancreatic stones are shown in Table 1. The
median age and follow-up were 69 years (range: 59–73
years) and 68 months (range: 36–180 months), respect-
ively. Seven patients (87.5%) had elevated serum IgG4
concentration, 5 patients (62.5%) were being treated with
prednisolone (PSL), and 4 patients (50%) had experi-
enced a relapse during the study period. The 92 patients
with ordinary CP, which included 70 patients with alco-
holic CP and 22 with idiopathic CP, presented at a me-
dian age of 56.5 years (range: 20–85 years) and consisted
of 77 men and 15 women.
Univariate analysis for comparisons between chronic
stage AIP and ordinary CP groups revealed that the AIP
group was significantly older (69.0 vs. 56.5 years, P = 0.018).Table 1 Characteristics of 8 patients with chronic stage
autoimmune pancreatitis
Case Age Gender Serum IgG4 Steroid treatment Relapse
(years) (male/female) (mg) (+/−) (+/−)
1 70 M 725 + +
2 64 M 965 + +
3 66 M 730 + +
4 73 M 185 - -
5 68 F 1110 + -
6 59 M 352 - -
7 71 M 36 - -
8 73 M 229 + +A tendency for male preponderance was seen in both
groups. Regarding indications for ESWL therapy, chronic
pain was significantly less frequent in the chronic stage
AIP group (0% vs. 45.7%, P = 0.001), while preservation of
pancreatic function was significantly more frequent (75%
vs. 19.6%, P = 0.001) (Table 2).
Treatment details
Stones located in the pancreatic head region were more
frequently subjected to ESWL treatment in both chronic
stage AIP and ordinary CP groups. However, pancreatic
duct stenosis proximal to stones tended to be more
frequent in the chronic stage AIP group (50% vs. 23.9%,









stones in MPD (+/−)
5/3 71/21 0.394




Relapse of pancreatic stones
in MPD (+/−)
1/7 22/70 0.678
AIP: autoimmune pancreatitis; CP; chronic pancreatitis; ESWL: extracorporeal
shock wave lithotripsy; MPD: main pancreatic duct.
*P < 0.05.
Figure 1 CT and ERCP findings in a 66-year-old man whose pancreatic stone was treated with ESWL to preserve pancreatic function.
(A), (B) CT before ESWL showing the pancreatic stone and pancreatic atrophy (arrows). (C), (D) ERCP before ESWL identifying the obstructing
X-ray-positive stone in the MPD (arrows) and pancreatic duct stenosis proximal to the pancreatic calculus (arrowheads). Pre-pancreatograpy (C) and
post-pancreatography (D) images.
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difference in the rate of combination ESWL and endo-
scopic treatment between the groups. We also found no
appreciable differences in the rates of ESWL combined
with individual endoscopic therapies, such as EPST, endo-
scopic pancreatolithotripsy, or EPS, between the groups
(Table 2).
Treatment outcomes
The complete extraction ratio of pancreatic stones from
the MPD tended to be lower in the chronic stage AIP
group than in the ordinary CP group (62.5% vs. 77.2%,
P = 0.394) (Table 2). As a Piezoelectric Lithotripter was
used for 39 cases before 2004 and a comparable Electro-
magnetic Lithotripter was adopted for 61 cases after-
wards, there were no remarkable differences in the
success rates of fragmentation or complete extraction
ratio.
A shift from medical to surgical treatment occurred in
1 patient (12.5%) with chronic stage AIP and 3 (3.3%)
with ordinary CP. This difference was not significant
(12.5% vs. 3.3%, P = 0.284) (Table 2). Surgical treatment
consisted of distal pancreatectomy in the AIP patient
(Figure 2) and distal pancreatectomy and pancreaticoje-
junostomy in 1 and 2 CP patients, respectively.
Eight patients (8.7%) with ordinary CP experienced
complications related to ESWL, as compared with none
with chronic stage AIP (0%). These rates were compar-
able (0% vs. 8.7%, P = 0.623) (Table 2). ESWL complica-
tions were defined as events that occurred within severaldays after the procedure and were classified as either
major, which needed further intervention, or minor,
which were relieved by conservative treatment. We wit-
nessed 4 of each complication type. Among the 4 cases of
major complications, 2 patients experienced lower bile
duct stricture that required endoscopic bile duct stenting
and choledochojejunostomy, respectively. The remaining
2 patients displayed an infected pancreatic cyst needing
endoscopic transpapillary drainage. All 4 minor complica-
tions were of mild acute pancreatitis that improved during
observation.
The recurrence of pancreatic stones in the MPD was
seen in 1 patient (12.5%) in the chronic stage AIP group at
56 months postoperatively and 22 patients (23.9%) with
ordinary CP. This difference was not significant (12.5% vs.
23.9%, P = 0.678) (Table 2).
Pathological analysis
We reviewed the postoperative histopathology of a patient
with chronic stage AIP who displayed a stone in the
pancreatic tail, suffered from repeated pancreatic at-
tacks, experienced several recurrences of pancreatic
stones following extraction by combination ESWL and
endoscopic therapy, and ultimately underwent distal
pancreatectomy to alleviate his symptoms (Figure 2).
In loupe images, the patient’s pancreatic parenchyma
exhibited abundant interlobular fibrosis that resembled
multiple tuberosities with sclerotic variation in addition
to several areas with lymphoplasmacytic sclerosing pan-
creatitis (LPSP) in which interlobular fibrosis was unclear
Figure 2 CT and ERCP findings in a 71-year-old man who experienced a pancreatic attack relapse and was treated with ESWL. (A), (B)
Contrast-enhanced CT before ESWL showing the pancreatic stone (arrows). (C), (D) ERCP before ESWL identifying the obstructing X-ray-positive
stone in the MPD (arrows). Pre-pancreatograpy (C) and post-pancreatography (D) images.
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findings of ordinary CP, such as mild inflammatory cell
infiltration, acinar atrophy, and scarce IgG4-positive
plasma cell infiltration, were present in intralobular
areas. Thick fibrosis was seen in interlobular areas. In
contrast, the latter regions displayed characteristic AIP
findings, including dense plasma cell and lymphocyte
invasion, storiform fibrosis, obliterative phlebitis, and
abundant IgG4-positive plasma cell infiltration in
intralobular areas and opaque fibrosis in interlobular
areas (Figure 4).Figure 3 Loupe image of chronic stage AIP (hematoxylin and eosin st
fibrosis that resembled multiple tuberosities with sclerotic variation (A) alon
(LPSP), in which interlobular fibrosis was unclear (B).Discussion
Is pancreatic calculus treatment of AIP different from that
of ordinary CP?
The present study uncovered the following observations
regarding ESWL treatment of pancreatic calculi in pa-
tients with chronic stage AIP or ordinary CP: (1) the
AIP group was significantly older than the CP group and
displayed fewer clinical symptoms requiring ESWL ther-
apy, (2) the AIP group showed frequent pancreatic duct
stenosis proximal to pancreatic calculi, (3) the rate of
complete stone extraction from the MPD was slightlyaining). Pancreatic parenchyma exhibited abundant interlobular
g with several areas of lymphoplasmacytic sclerosing pancreatitis
Figure 4 Histological image of chronic stage AIP. (A), (C), (D) Characteristics of ordinary CP. Mild inflammatory cell invasion, acinar atrophy,
and slight IgG4-positive plasma cell infiltration are present in intralobular areas. Thick fibrosis is observed in interlobular areas. (B), (E), (F) Characteristics
of AIP. Dense plasma cell and lymphocyte invasion, storiform fibrosis, obliterative phlebitis, and abundant IgG4-positive plasma cell infiltration exist in
intralobular areas. Opaque fibrosis is present in interlobular areas. Hematoxylin and eosin staining, low-power field (×40) (A, B), hematoxylin and eosin
staining, high-power field (×400) (C, E), and IgG4 immunostaining, high-power field (×400) (D, F) images.
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differences in the rates of subsequent surgical treatment,
adverse effects, or pancreatic stone recurrence after
ESWL between the groups.
In this investigation, we enrolled 100 patients with
chronic calcified pancreatitis who had undergone ESWL.
The indications for ESWL were: (1) obstructing stone in
the MPD whose volume was deemed too large for
endoscopic therapy and (2) chronic pain or repeated
pancreatitis attacks, as well as (3) preservation of pan-
creatic function by pancreatic juice release. All patients
provided informed consent for this treatment.
Of the 73 patients with AIP who were registered at
our hospital, 15 (20%) later experienced calculi formation
that met the Japanese diagnostic criteria for ordinary CP.
Among them, several patients who fulfilled the indications
for ESWL did not consent to treatment, which was a limi-
tation of this study. As we aimed to evaluate pancreatic
stone treatment, we selected only the 8 patients with
chronic stage AIP who had met the requirements for
ESWL and had provided consent after being explained all
possible complications, such as acute pancreatitis, and the
risk of non-preservation of pancreatic function. Larger
prospective comparisons of chronic stage AIP and ordin-
ary CP are required.
Many patients with calcified ordinary CP complain of
epigastralgia and back pain due to increased pancreatic
duct pressure caused by intraductal pancreatic stones[38]. However, this study revealed that only 12% of AIP
patients who were treated with ESWL displayed these
symptoms. We earlier identified severe inflammation of
the pancreatic head and non-narrowing of the pancreatic
duct in the body region, both of which indicated that se-
vere pancreatic juice stagnation had induced pancreatic
calcification, to be risk factors for extensive pancreatic
stone formation in AIP [27,29]. Accordingly, we had ex-
pected that AIP complicated with numerous pancreatic
calculi would be accompanied by epigastralgia similarly
to ordinary CP, but the present study showed that most
AIP patients were asymptomatic. Although AIP and or-
dinary CP both displayed the imaging findings of severe
pancreatic calculi and pancreatic atrophy that were char-
acteristic of a chronic stage of pancreatitis, there was a
discrepancy in the occurrence of abdominal pain be-
tween the two conditions. The reason for this difference
may be pathophysiological differences that require fur-
ther study.
In our cohort, ESWL was performed on AIP patients
mainly to preserve pancreas function. Previous reports
have examined the efficacy of pancreatic calculus treat-
ment by endoscopy and ESWL on pancreatic exocrine
and endocrine function in ordinary CP. In terms of exo-
crine function, a BT-PABA test showed improvement in
60-77% of cases [32,33], although several studies found
no significant differences before and after therapy. Con-
cerning endocrine function, few reports have been able
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or insulin secretion capacity following treatment [34,39].
In patients with chronic calcified pancreatitis who re-
ceive treatment for the purpose of function preservation,
it will be of merit to evaluate whether pancreatic condi-
tion is affected by relevant therapy. However, as this
study focused primarily on pancreatic stone treatment
approaches, detailed pancreatic function readings were
not obtained before and after intervention. The BT-
PABA test is the standard pancreatic exocrine function
examination in Japan, but it is affected by various fac-
tors, such as liver and renal dysfunction, and is some-
what complex for patients to understand. It will be
important to perform precise assessment of exocrine
and endocrine dysfunction in chronic stage AIP over a
long-term period that includes the presence or absence
of pancreatic stone treatment. We have also been con-
sidering new alternative approaches to the BT-PABA
test.
We previously proposed that AIP could exhibit severe
pancreatic stone formation over a long-term period due
to disease recurrence [17,20] and pancreatic juice stasis
preceded by pancreatic head swelling, narrowing of both
Wirsung’s and Santorini’s ducts in the affected region,
and MPD non-narrowing in the pancreatic body
[27,29,30]. Another risk factor for pancreatic calculus
formation in AIP is excessive alcohol intake of pure
ethanol of >50 g/day [40]. There was 1 alcoholic subject
among the 8 AIP patients who received calculus treat-
ment with ESWL. In this patient, both pancreatic juice
stagnation due to AIP-specific inflammation [27,29] and
pancreatic juice denaturation from alcohol abuse might
have been associated with the calculi. Further examin-
ation is required on alcohol consumption and the clin-
ical background of pancreatic stone formation in AIP.
When assessing the suitability of ESWL treatment, it
is important to identify patients having cancer of the
pancreas. Subjects with pancreatic cancer were excluded
from this investigation after extensive examination, al-
though it should be noted that pancreatic stones make it
challenging to detect pancreatic tumors. All ESWL pa-
tients were free from pancreatic cancer during the entire
study period.
What are effective approaches for the treatment of AIP
with ESWL?
The present study uncovered a tendency for increased
pancreatic duct stenosis proximal to pancreatic stones in
AIP that was unlike the widely distributed duct stenosis
encountered in ordinary CP. In such AIP patients, the
stones fragmented by ESWL may sometimes have diffi-
culty passing through the narrowed duct in the head re-
gion, which might diminish the efficacy of endoscopic
treatment. Pancreatic duct dilation is a useful techniqueto remove crushed calculi pieces following ESWL in or-
dinary CP with pancreatic duct stenosis. Here, duct sten-
osis proximal to pancreatic calculi was present in 4 of 8
AIP patients (50%). Endoscopic pancreatic duct dilation
was performed on 1 patient, which resulted in complete
stone extraction. Thus, similarly to ordinary CP, combin-
ation therapy of endoscopic pancreatic duct dilation and
ESWL in AIP may constitute an effective procedure to
remove pancreatic stones in the presence of proximal
duct stenosis.
We observed that pancreatic calculus treatment in
AIP was significantly more common in elderly people
who exhibited fewer symptoms in the present study. Ac-
cordingly, intensive ESWL and endoscopic treatment
may be avoided or postponed in patients with the factors
of: (1) advanced age, (2) mild or no chronic pain or pan-
creatitis, and (3) pancreatic duct stenosis proximal to
pancreatic calculi. For such cases, we suggest conser-
vative follow-up that includes periodic blood tests and
imaging studies. Regular evaluation of exocrine and
endocrine function during long-term follow-up will also
help assess the need and timing of ESWL and endo-
scopic treatment in chronic AIP patients with pancreatic
stones.
In ordinary CP, the most important factor in prevent-
ing calculus recurrence is avoidance of alcohol. However,
treatment for pancreatic duct stenosis is thought to be
another important step [41]. In AIP, MPD stenosis may
affect not only the efficacy of pancreatic stone treatment,
but also pancreatic stone recurrence afterwards. Further-
more, previous studies have reported that smoking sta-
tus (not smoking or cessation) was related to the efficacy
of ESWL and pain relief after ESWL for CP [36,42]. Al-
though this investigation did not evaluate smoking
habits, further examination is needed in comparisons
between ordinary CP and chronic stage AIP. Careful
follow-up to evaluate calculus recurrence and exacer-
bation is also required for AIP with pancreatic stones,
regardless of any ESWL or endoscopic treatment.
Is the histopathology of chronic stage AIP different from
that of ordinary CP?
Although ordinary CP and chronic stage AIP exhibit
similar imaging findings, including pancreatic calculus
formation and pancreatic atrophy, their clinical manifes-
tations, such as chronic pain and pancreatitis attacks,
appear to be different. From the viewpoint of long-term
pancreatic exocrine and endocrine function, it will be of
interest to clarify whether the histopathology of ordinary
CP is in fact different from that of chronic stage AIP
with pancreatic stones. Since there have been few re-
ports describing this relationship, we examined the
pancreatic histopathology of an AIP patient who experi-
enced pancreatic calculus relapse after surgical treatment
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served that the nodular pancreatitis characteristic of or-
dinary CP was widespread in tissue samples, while LPSP,
which was typical of AIP, was found in restricted areas
only. From these findings, we considered the following
possibilities as mechanisms of chronic stage AIP histo-
pathology: (1) based on our previous reports that AIP
could progress to CP with severe calcification over a long-
term period [27,29], LPSP may have shifted to a histopath-
ology similar to that of ordinary CP, (2) due to the patient’s
history of alcoholism, LPSP may have been complicated
with a histopathology of typical alcoholic pancreatitis, and
(3) based on the findings of Fukui et al. that obstructive
pancreatitis complicated with pancreatic cancer also re-
vealed abundant IgG4-bearing plasma cell infiltration [43],
LPSP with marked IgG4-bearing plasma cell infiltration
may have coexisted with obstructive pancreatitis. Al-
though we followed the clinical outcome of a single pa-
tient, our findings suggested that AIP could shift to a
clinical condition similar to that of ordinary CP not only
in imaging findings, but also in pancreatic histopathology,
over a long-term course. Further analysis of the pancreatic
histopathology of AIP with pancreatic atrophy and calculi
is needed to clarify the clinical conditions of advanced
stage AIP.
In the present study, there are several limitations and
future perspectives. Specifically, our investigation in-
cluded a limited number of patients and was retrospect-
ive in nature. It also employed the revised JCDC for CP,
which has a strong emphasis on imaging findings, and
the subjects enrolled all had type 1 AIP. More detailed
analyses of physical findings and exocrine and endocrine
dysfunction are needed as well.Conclusions
The present study presented the clinical features and
outcomes of patients with AIP who underwent ESWL
treatment for severe pancreatic calculi. We postulate
from our results using a limited number of patients that
the approach for pancreatic stone treatment in AIP may
be different from that in CP, whereby intensive ESWL
treatment may be avoided or delayed if patients show:
(1) advanced age, (2) little or no chronic pain or pan-
creatitis, and (3) pancreatic duct stenosis proximal to
pancreatic calculi. In such cases, the benefit of ESWL
treatment may be outweighed by the risks involved in
this procedure.
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